Evidence map›Paper›PMID 42746482›Full record

ArticleFrontiers in medicine2026

Successful induction of remission with azacitidine, venetoclax, and dasatinib followed by allogeneic hematopoietic stem cell transplantation in a patient with Philadelphia chromosome-positive mixed phenotype acute leukemia (B/myeloid): a case report.

Juan Zhang, Yan Huang, Liangkui Luo, Kaikai Huang, Yanbin Pang

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan ZhangDepartment of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
Yan HuangDepartment of Hematology, The Shenzhen Integrated Traditional Chinese and Western Medicine Hospital, Shenzhen, China.
Liangkui LuoDepartment of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
Kaikai HuangDepartment of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
Yanbin PangDepartment of Hematology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph Case presentation: A 32-year-old man presented with a one-week history of fever. Bone marrow examination revealed 83% blasts with two distinct populations: lymphoblasts and monoblasts, confirming bilineal B/myeloid MPAL. Karyotyping showed 45, XY,-7, t(9;22)(q34;q11.2), and the Conclusion: An induction regimen based on azacitidine, venetoclax, and dasatinib may represent a safe and effective therapeutic strategy for adult patients with Ph

Indexed as

azacitidinecase reportdasatinibPh+ MPALvenetoclax

Identifiers

PMID42746482
PMCPMC13576452

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.